Elderly AML & Larotrectinib
from OncoPharm Hosted by John Bossaer
The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication). Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 26 minutes long.
When was this OncoPharm episode published?
This episode was published on November 27, 2018.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.